Pipeline
We are advancing molecular glue degraders for high-confidence, intractable targets with significant unmet patient needs. Our pharmaceutical partnerships enable the pursuit of broader indications and amplify the impact of our discoveries.
Program
Indication
Discovery
IND-Enabling
Phase 1
Partner
NEO-811
ARNT/HIF-1β
ccRCC*
Discovery
IND-Enabling
Phase 1
Undisclosed
Solid Tumors
Discovery
IND-Enabling
Phase 1
Undisclosed
Solid Tumors
Discovery
IND-Enabling
Phase 1
Early Pipeline
Multiple Indications
Discovery
IND-Enabling
Phase 1
Defined Targets
Oncology / Immunology
Discovery
IND-Enabling
Phase 1
Defined Targets
Neurology
Discovery
IND-Enabling
Phase 1
Defined Targets
Cardiometabolic / Rare
Discovery
IND-Enabling
Phase 1
* ccRCC = clear cell renal cell carcinoma